title: SHIfT: Ivabradine's additional clinical benefits regardless of background beta-blocker dose.
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D054143:Heart Failure, Systolic / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects*; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D000077550:Ivabradine; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D001552:Benzazepines; D002317:Cardiovascular Agents; D000077550:Ivabradine